Quoin Pharmaceuticals highlights continued growth of NETHERTON NOW program

In recognition of Rare Disease Day 2026, Quoin Pharmaceuticals (QNRX) highlighted the continued growth of its NETHERTON NOW awareness campaign, which seeks to amplify the voices of patients, caregivers and clinicians impacted by Netherton Syndrome, a rare genetic disease with no approved treatment or cure. “When we launched NETHERTON NOW at the beginning of Rare Disease Month last year, we hoped it would resonate, but the response has far surpassed anything we anticipated,” said Denise Carter, Co-Founder and Chief Operating Officer of Quoin Pharmaceuticals. “Nearly 2 million video views and more than 24 million impressions later, what stands out most is the courage of the patients and families who chose to share their experiences. Individuals who had previously lived in silence with their suffering at the hands of this disease now have a platform to share their stories, connect with one another, and help bring greater understanding of Netherton Syndrome to the broader medical and advocacy communities. That expanded awareness is exactly what this campaign was meant to create.”